Maurizio Fava, MD

Linkedin Team icon

Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)

Dr. Maurizio Fava is Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH), director, Division of Clinical Research of the MGH Research Institute, executive director of the Clinical Trials Network and Institute, (MGH), associate dean for clinical and translational research and the Slater Family Professor of Psychiatry at Harvard Medical School.

Dr. Fava is a world leader in the field of depression. He has edited eight books and authored or co-authored more than 800 original articles published in medical journals with international circulation, articles which have been cited more than 80,000 times in the literature and with an h index of over 140. Dr. Fava obtained his medical degree from the University of Padova School of Medicine and completed residency training in endocrinology at the same university. He then moved to the United States and completed residency training in psychiatry at MGH. He founded and was director of the hospital’s Depression Clinical and Research Program from 1990 until 2014. Under Dr. Fava’s direction, the Depression Clinical and Research Program became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. In 2007, he also founded and is now the executive director of the MGH Psychiatry Clinical Trials Network and Institute, the first academic CRO specialized in the coordination of multi-center clinical trials in psychiatry.

Dr. Fava has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $120 million. Dr. Fava’s prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly-acting antidepressant therapies.

Dr. Fava has received several awards during his career and is on the editorial board of five international medical journals. Since 1990, Dr. Fava has also mentored more than 50 trainees who have gone on to become lead investigators in the area of psychiatry. He has developed with Dr. David Schoenfeld a novel design (with over five patents) to address the problem of excessive placebo response in drug trials and to markedly reduce sample size requirements for these trials. In 2009, Dr. Fava received the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School, and in 2013 the John T. Potts, Jr., MD Faculty Mentoring Award from Massachusetts General Hospital. He is also the former President of the American Society of Clinical Psychopharmacology.

Paul Summergrad, MD

Professor of Psychiatry and Medicine at Tufts University School of Medicine and Chairman Emeritus of the department of psychiatry at Tufts Medical Center

Nzinga Harrison, MD

Co-Founder & Chief Medical Officer, Eleanor Health

Carol Vallone

Chair of the Board of Directors, Member of Compensation Committee, Member of Audit Committee

Andreas Krebs

Vice Chair of the Board of Directors, Member of Nomination & Governance Committee, Member of Audit Committee

David Gryska

Board Director, Chair of Audit Committee

Roger Crystal, MD

Board Director, Chair of Nomination & Governance Committee, Member of Compensation Committee

Robert Barrow

Chief Executive Officer and Board Director

Suzanne Bruhn, PhD

Board Director, Chair of Compensation Committee, Member of Nomination & Governance Committee

Miri Halperin Wernli, PhD

Executive President

Daniel Karlin, MD, MA

Chief Medical Officer

Stephanie Fagan, MS

Chief Corporate Affairs Officer

Carrie Liao, CPA

Chief Accounting Officer

Francois Lilienthal, MD, MBA

Chief Commercial Officer

Gregg Pratt, PhD

Chief Regulatory and Quality Assurance Officer

Mark Sullivan, JD

Chief Legal Officer and Corporate Secretary

Robert Malenka, MD, PhD

Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University

Peter Bergethon, MD

Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.

Robert Dworkin, PhD

Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry at University of Rochester

Maurizio Fava, MD

Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)

Carole Abel, MBA

VP, Programs and Portfolio Office

Phong Duong, PharmD

VP, Global Market Access and Health Economics

Peter Mack, PhD

VP, Pharmaceutical Development

Rafael Muniz, MD

VP, Global Medical Affairs

Javier Muniz, MD

VP, Research and Development Strategy

Michael Seggev

VP, Global Marketing, Strategic Insights and Digital Innovation

Maria Oquendo, MD, PhD

Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania, Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania

Matthias Liechti, MD, PhD

Scientific Collaborator & Advisor

Kim PC Kuypers, PhD

Scientific Collaborator & Advisor

Peter Gasser, MD

Clinical Advisor
×

Thanks for visiting!

You are leaving MindMed and will be automatically redirected to ${url} in a moment.

Change your mind?

Return to Mindmed